United States · FDA National Drug Code directory
Tafinlar
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0078-1154_6c546993-1f7f-409b-b108-60f22e9b948a
- Product NDC
- 0078-1154
- Form
- TABLET, FOR SUSPENSION
- Composition / generic term
- dabrafenib
- Labeler
- Novartis Pharmaceuticals Corporation
- Marketing category
- NDA
- Marketing start / end (source format)
- 20230316
- Source listing expiry
- 20271231
Source-listed ingredients
- DABRAFENIB MESYLATE — 10 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 210 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-1154-21) · 0078-1154-21
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →